Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AOXING PHARMACEUTICAL COMPANY, INC. (AXN)
|
Add to portfolio |
|
|
|
| Price: |
$0.12
| | Metrics |
| OS: |
76.2
|
M
| |
-8
|
% ROE
|
| Market cap: |
$9.15
|
M
| |
-1
|
% ROIC
|
|
Net debt:
|
$20.5
|
M
| |
10.4
|
x Debt/EBITDA
|
|
EV:
|
$29.7
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$2.0
|
M
| |
15.0
|
x EV/EBITDA
|
|
EBIT
|
$995.8
|
k
| |
29.8
|
x EV/EBIT
|
| EPS |
($0.02)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Jun-30-16 | Jun-30-15 | Jun-30-14 | Jun-30-13 | Jun-30-12 | Jun-30-11 | Jun-30-10 | Jun-30-09 |
| Revenues | 32.3 | 25.5 | 12.7 | 10.8 | 8.1 | 6.7 | 6.1 | 8.9 |
| Revenue growth | 26.9% | 100.0% | 17.6% | 33.1% | 22.3% | 8.8% | -31.6% | 26.6% |
| Cost of goods sold | 7.8 | 5.7 | 6.9 | 4.6 | 3.2 | 3.3 | 2.3 | 5.1 |
| Gross profit | 24.6 | 19.8 | 5.8 | 6.3 | 4.9 | 3.3 | 3.8 | 3.8 |
| Gross margin | 75.9% | 77.7% | 45.6% | 57.9% | 60.2% | 50.0% | 61.7% | 42.6% |
| Sales and marketing | 11.6 | 7.5 | 4.4 | 7.4 | 1.8 | 1.6 | 1.4 | 1.5 |
| Research and development | 3.1 | 0.3 | 0.6 | 1.5 | 0.6 | 0.9 | 1.5 | 0.7 |
| General and administrative | 3.1 | 2.8 | 3.6 | 3.3 | 3.1 | 5.1 | 3.8 | 3.5 |
| EBIT | 6.3 | 8.8 | -3.2 | -6.4 | -1.0 | -4.9 | -3.6 | -4.0 |
| EBIT margin | 19.5% | 34.5% | -25.4% | -59.4% | -12.5% | -73.0% | -58.6% | -44.8% |
| Pre-tax income | 2.9 | 3.1 | -8.6 | -17.3 | -15.9 | -4.4 | -0.9 | -6.0 |
| Income taxes | 0.6 | -2.7 | 0.0 | 0.0 | -0.1 | 3.4 | -0.1 | -3.3 |
| Tax rate | 22.3% | | 0.0% | 0.0% | 0.4% | | 6.9% | 54.9% |
| Net income | 2.1 | 5.5 | -8.6 | -17.3 | -15.8 | -7.4 | -0.8 | -2.7 |
| Net margin | 6.4% | 21.6% | -67.8% | -159.7% | -194.5% | -111.4% | -13.8% | -30.1% |
| |
| Diluted EPS | $0.03 | $0.09 | ($0.17) | ($0.35) | ($0.32) | ($0.16) | ($0.02) | ($0.07) |
| Shares outstanding (diluted) | 75.5 | 63.2 | 49.9 | 49.7 | 49.3 | 46.6 | 45.6 | 41.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|